- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04833387
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
January 9, 2023 updated by: Pei-Rong Ding, Sun Yat-sen University
PD-1 Antibody as a Sequential Therapy Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer: an Open, Multi-center, Phase II Clinical Trial
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal cancer staged as locally advanced (cT3-T4N+/-M0 for rectal cancer).
This treatment will be given during the window period until surgical resection of the tumor.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- 651 Dongfeng Road East
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who personally provided written consent for participation in the study
- Treatment-naive patients with rectal cancer, in whom the inferior margin of the tumor was at a distance of 12 cm or less from the AV before CRT
- Primary rectal cancer histopathologically confirmed to be adenocarcinoma
- Clinical stage of T3,and T4 ,N any,M0,before CRT
- Macroscopic radical resection could be feasible, based on diagnostic imaging before CRT
- Patients with the ECOG performance status of 0 or 1 at the time of enrollment
- Patients without distant metastasis on the imaging test before CRT
- Preoperative biopsy of tumor immunohistochemistry TPS>1% or CPS>1
- Life expectancy of greater than 2 years
- No signs of intestinal obstruction; or the obstruction has been relieved after the proximal colostomy operation
- Hematology: WBC>4000/mm3; PLT>100000/mm3; Hb>10g/dL
- Liver function: SGOT and SGPT are less than 1.5 times the normal value; bilirubin is less than 1.5mg/dL
- Renal function: creatinine <1.8mg/dL Others: non-pregnant or breast-feeding women; no other malignant diseases (except for non-melanoma or cervical carcinoma in situ) within 5 years or during the same period; no mental illness that causes the inability to obtain informed consent; no other serious diseases that can shorten the survival time disease.
- Have not received rectal surgery in the past;
- Have not received chemotherapy or radiotherapy in the past;
- Have not received biological treatment in the past;
- Past endocrine therapy: unlimited.
Exclusion Criteria:
- Rectal cancer with unstable microsatellite (MSI or dMMR);
- Preoperative biopsy of tumor immunohistochemistry TPS≤1% or CPS≤1
- Known history of human immunodeficiency virus (HIV) or chronic hepatitis B or C (high copy viral DNA);
- Autoimmune diseases;
- Other active clinical serious infections (>NCI-CTC version 3.0);
- Patients in clinical phase I;
- There is evidence that there is distant metastasis before surgery;
- Cachexia, decompensation of organ function;
- Have a history of pelvic or abdominal radiotherapy;
- Multiple primary cancers;
- Patients who need treatment for seizures (such as steroids or anti-epileptic treatment);
- Have a known additional malignant tumors within 5 years. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;
- Chronic inflammatory bowel disease, intestinal obstruction;
- Drug abuse and medical, psychological or social conditions may interfere with patients' participation in research or have an impact on the evaluation of research results;
- Known or suspected to be allergic to the study drug or to any drug given in connection with this test;
- Any unstable conditions or situations that may endanger patient safety and compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD-1 antibody + capecitabine + radiation
|
Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response
Time Frame: 1 year
|
Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival (OS)
Time Frame: 3 years
|
3 years
|
Relapse-free survival (RFS)
Time Frame: 3 years
|
3 years
|
Clinical complete response (CCR)
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Anticipated)
December 31, 2024
Study Completion (Anticipated)
December 31, 2026
Study Registration Dates
First Submitted
April 4, 2021
First Submitted That Met QC Criteria
April 4, 2021
First Posted (Actual)
April 6, 2021
Study Record Updates
Last Update Posted (Estimate)
January 11, 2023
Last Update Submitted That Met QC Criteria
January 9, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2019-092
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Carcinoma
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal CarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingPembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Wuhan Union Hospital, ChinaNot yet recruitingRecurrent Colorectal Carcinoma | Advanced Colorectal CarcinomaChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Carcinoma | Colorectal Adenoma and CarcinomaNetherlands
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Center for Advancing Translational Sciences (NCATS)Not yet recruitingRecurrent Colorectal Carcinoma | Locally Advanced Colorectal Carcinoma | Stage III Colorectal CancerUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
Clinical Trials on PD-1 antibody
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsRecruitingNasopharyngeal Carcinoma | Surgery | PD-1China
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.Completed
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingNasopharyngeal Carcinoma
-
Henlix, IncUnknown
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Metastatic | MSSChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States